Market Cap: $2.07B
BI
BioCryst Pharmaceuticals, Inc.
BCRX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $2.07B
BioCryst Pharmaceuticals (Ticker: BCRX) recently advances its commitment to improving treatment options for Hereditary Angioedema (HAE) patients with new clinical data presented at the EAACI 2026 meet…
Biocryst Pharmaceuticals reaffirms its dedication to advancing treatment options for hereditary angioedema through two key initiatives: the established ORLADEYO treatment and the investigational monoc…
BioCryst Pharmaceuticals (Ticker: BCRX) showcases its commitment to advancing treatment for hereditary angioedema as it prepares for the EAACI Annual Meeting, scheduled for June 12-15, 2026, in Istanb…
BioCryst Pharmaceuticals, a company listed on Nasdaq (Ticker: BCRX), has recently made headlines through a strategic licensing agreement with Neopharmed Gentili. This agreement specifically pertains t…
BioCryst Pharmaceuticals: Advancements in Rare Disease Treatments Highlighted in Q4 Earnings Report BioCryst Pharmaceuticals (NASDAQ:BCRX) presents a compelling narrative in its fourth-quarter earning…
BioCryst Pharmaceuticals: A Strong Finish to the Fiscal Year and a Promising Future BioCryst Pharmaceuticals (NASDAQ:BCRX) announces its fourth-quarter earnings, reflecting solid progress in the bioph…
BioCryst Pharmaceuticals Gains FDA Approval for Pediatric HAE Treatment In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved BioCryst Pharmaceuticals Inc.'s oral pellet for…
BioCryst Pharmaceuticals Secures FDA Approval for Pediatric HAE Treatment BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) achieves a significant milestone as the U.S. Food and Drug Administration (FDA) gr…
Biocryst Pharmaceuticals Eyes Market Position Amid Earnings Landscape As Biocryst Pharmaceuticals navigates its place in the biopharmaceutical industry, the current earnings season provides a backdrop…
Biocryst Pharmaceuticals: Advancements in Rare Disease Treatments Shape Future Prospects Biocryst Pharmaceuticals is at the forefront of developing innovative therapies for rare diseases, particularly…
BioCryst Pharmaceuticals Expands Portfolio with Strategic Acquisition of Astria Therapeutics In a significant move to strengthen its position in the biotechnology sector, BioCryst Pharmaceuticals, Inc…
BioCryst Pharmaceuticals Expands Portfolio with Strategic Acquisition of Astria Therapeutics BioCryst Pharmaceuticals, Inc. has announced a significant strategic acquisition of Astria Therapeutics, In…
BioCryst Pharmaceuticals Expands Portfolio through Strategic Acquisition of Astria Therapeutics BioCryst Pharmaceuticals, Inc. announces a significant strategic move by acquiring Astria Therapeutics,…
Innovative Treatment for Hereditary Angioedema: A New Era in Patient Care Ionis Pharmaceuticals, Inc. celebrates a significant milestone with the U.S. Food and Drug Administration's (FDA) recent appro…
FDA Approval of IONS Dawnzera: A Breakthrough for Hereditary Angioedema Treatment The recent approval of IONS Dawnzera (donidalorsen) by the U.S. Food and Drug Administration (FDA) marks a significant…
BioCryst Pharmaceuticals Gears Up for Earnings Release Amid Pipeline Developments BioCryst Pharmaceuticals, a key player in the biotechnology sector, is poised to unveil its quarterly earnings report…
BioCryst Pharmaceuticals Prepares for Earnings Report: A Focus on Rare Disease Treatments BioCryst Pharmaceuticals, a biopharmaceutical company specializing in innovative therapies for rare diseases,…
BioCryst Pharmaceuticals Reports Strong Q1 Sales, Indicating Robust Market Demand BioCryst Pharmaceuticals, Inc. (BCRX) showcases significant growth in its first-quarter financial results, reporting s…
BioCryst Pharmaceuticals Reports Strong First-Quarter Sales Growth BioCryst Pharmaceuticals, Inc. (BCRX) delivers an impressive performance in its first-quarter earnings report, showcasing a significa…